Andersen, Martin Færch
Roed, Kickan
Sørensen, Victor
Riis, Allan
Rafn, Bolette Skjødt
Ebdrup, Bjørn Hylsebeck
Midtgaard, Julie
Funding for this research was provided by:
TrygFonden,Denmark (151603, 151603, 151603, 151603)
Article History
Received: 10 August 2023
Accepted: 28 February 2024
First Online: 26 March 2024
Declarations
:
: In addition to receiving written and oral information about the nature of the study prior to participation, all participants provided written informed consent and were guaranteed anonymity and confidentiality. The study was conducted in accordance with the Declaration of Helsinki. The Regional Ethics Committee of Northern Denmark has confirmed that no formal ethical approval was required (Case No. 2023000206) for the current study.
: Not applicable.
: BHE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S.MFA, KR, VS, AR, BSR and JM declare no competing interests.